ClinicalTrials.gg
CompletedNCT07365735XTENDUpdated Nov 13, 2026Results posted

TearCare MGX™ System With and Without Warming Hold

An interventional study of localized heat therapy in Meibomian Gland Dysfunction (Disorder), sponsored by Sight Sciences, Inc.. Completed at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Sight Sciences, Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 13, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Meibomian Gland Dysfunction with a site in United States — 7 open to participants now, 11 under way, none of them phase 3. Meibomian Gland Dysfunction · United States.

Enrollment
50th of 62
21 · median 44
Started
2026
with 5 others
No phase
43 of 64
4 open now
Registered
60th of 64
by date
Lead sponsor
3 of 64
Sight Sciences, Inc.

Among the 64 studies in Meibomian Gland Dysfunction with a site in United States, this one is the 50th largest by enrollment of the 62 interventional ones that give a count, is one of 6 that started in 2026, is one of 43 with no phase, and was the 60th registered.

Meibomian Gland Dysfunction

173 studies on the registry are indexed under Meibomian Gland Dysfunction; 23 are open to participants now.

Browse Meibomian Gland Dysfunction studies →

Open to participants now

7 of the 64 studies in Meibomian Gland Dysfunction with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Meibomian Gland Dysfunction studies recruiting now, 10 (77%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Meibomian Gland Dysfunction with a site in United States, or all of them as a file.
02

Study summary

TearCare is an office-based thermal therapeutic eyelid technology cleared by the US Food and Drug Administration for the treatment of evaporative dry eye disease due to meibomian gland dysfunction. In this randomized study, TearCare procedures using the TearCare MGX System (study device) with the extended Warming hold feature will be compared with TearCare procedures using the TearCare MGX System without the Warming hold (control group).

Read the detailed description

This study will collect data to assess the clinical utility of the Warming Hold period. The TearCare MGX Warming hold is a 10-minute period beyond completion of the Core Therapy time that serves to preserve elevated temperature by outputting only enough energy to maintain heat at the lowest setting of the system. At the minimum warmth setting the SmartLid device surfaces provide a steady state temperature of 39.0°C.

This is a prospective, randomized, assessor-masked, single-center, non-significant risk (NSR) study. To reduce potential bias in the study, study staff performing the endpoint assessments will be masked. Subjects will also be masked as to group assignment.

In this randomized study, TearCare procedures using the TearCare MGX System (study device) with the extended Warming hold feature will be compared with TearCare procedures using the TearCare MGX System without the Warming hold (control group).

TearCare procedures in this study will include an in-office eyelid debridement, 15-minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects will receive one in-office TearCare procedure at the Procedure Visit.

03

Conditions studied

  • Meibomian Gland Dysfunction (Disorder)

Keywords

  • TearCare
  • XTEND
  • Meibomian Gland Dysfunction
  • MGD
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, 22 years of age or older
  2. Reports dry eye symptoms within the past 6 months
  3. OSDI score of 23 to 79
  4. Meibomian gland obstruction in both eyes based on a total Meibomian Gland Secretion Score ≤12 in each eye.
  5. At least 15 glands in each lower eyelid should be expressible, with a sterile cotton swab, at the slit lamp.
  6. Best corrected visual acuity of 20/100 or better, OU.
  7. Willing and able to comply with the study procedures and follow-up
  8. Understands and signs the .

Exclusion criteria

Exclusion Criteria:

  1. Use of:

    1. Cyclosporine, Xiidra, or serum tears within 60 days prior to Screening;
    2. Antihistamines (oral or topical) within 7 days prior to Screening;
    3. Oral tetracyclines or azithromycin within 30 days prior to Screening;
    4. Topical ophthalmic antibiotics, anti-glaucoma medications, , non-steroidal anti-inflammatory medications within 30 days prior to Screening
    5. Isotretinoin (e.g. Accutane) at any time.
  2. Any of the following dry eye treatments:

    1. Office-based dry eye treatment (e.g. IPL, TearCare, thermal pulsation [LipiFlow], iLux etc.) within 12 months prior to Screening either as part of routine care or clinical investigation;
    2. Planned or recent surgical procedures to the eye or eyelid (90 days prior to Screening);
    3. Meibomian gland expression within 6 months prior to Screening;
    4. Blephex or debridement within 3 months prior to Screening;
    5. Punctal occlusion (including collagen, e.g. Soft Plug, UltraPlug, or crosslinked hyaluronic acid, e.g. Lacrifill) or punctal plugs within 15 days of the Screening visit;
    6. Use of tear neurostimulators (i.e., True Tear, iTear100, Tyrvaya) within 2 weeks of the baseline visit. (Subjects must refrain from using tear neurostimulators for the duration of the study);
    7. Any history of meibomian gland probing.
  3. History of eyelid, conjunctiva, or corneal surgery (including refractive surgery) within 12 months prior to Screening.
  4. Any history of chalazion surgery, surgery on the tarsal conjunctiva, radial keratotomy (RK), complicated blepharoplasty, lid reconstruction, or significant complications post-refractive surgery.
  5. Contact lens use within 2 weeks of the Procedure visit. Subjects presenting at the Screening visit using contact lenses must agree to discontinue use for a full 2 weeks (14 days) prior to the Procedure visit.
  6. Active hordeolum, stye, or chalazion at the time of the Screening visit.
  7. History of Herpes Simplex or Herpes Zoster of the eye or eyelid.
  8. Any active, ocular or peri-ocular infection, inflammation, or irritation.
  9. Recurrent clinically significant eye inflammation, other than dry eye, within 3 months prior to Screening.
  10. Clinically significant anterior blepharitis. In addition, collarettes or flakes of more than one quarter of the eyelid are excluded.
  11. Clinically significant eyelid abnormalities in either eye (e.g. entropion/ectropion, blepharospasm, aponeurotic ptosis, lagophthalmos, distichiasis, trichiasis).
  12. Clinically significant dermatologic or cutaneous disease of the eyelid or periocular area.
  13. In the clinical judgement of the Investigator, meibomian glands have significant capping, atrophy, or are unable to be expressed, digitally or with a cotton swab.
  14. Corneal surface abnormalities such as corneal epithelial defects (other than punctate staining), ulcers, corneal epithelial dystrophies, keratoconus, and ectatic disease of the cornea
  15. Any active, clinically significant allergic, vernal, or giant papillary conjunctivitis.
  16. Ocular trauma within 3 months prior to Screening.
  17. Known history of diminished or abnormal facial, periocular, ocular or corneal sensation
  18. Systemic diseases, in the Investigator's medical judgement, resulting in dry eye (e.g. diseases such as Sjogren's syndrome, rheumatoid arthritis, lupus, Graves' disease, sarcoidosis, etc.)
  19. Subject is currently using Retin A /Retin A derivatives.
  20. Subject has permanent eyeliner/lid tattoos, eyelash extensions or wears false eyelashes.
  21. Subject is currently using Latisse, Lash Boost or any other type of eyelash growth serum. Prostaglandin analog products such as Latisse should not be used within 30 days of the Screening visit.
  22. Temporary false eyelashes, lash extensions, or any other type of false eyelash within 15 days of the Screening Visit.
  23. Allergies to silicone tissue adhesives, acrylates and/or copper.
  24. Subject has a pacemaker or implantable cardiac defibrillators (ICD).
  25. Co-existing condition, either ocular or non-ocular that, in the judgement of the Investigator could affect the safety or effectiveness of treatment or the compliance of the subject to the protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Active comparator
    TearCare MGX with Warming Hold

    15 minute thermal treatment with TearCare MGX followed by 10 minute warming hold

    Device: localized heat therapy

  • Active comparator
    TearCare MGX without Warming Hold

    15 minute thermal treatment with TearCare MGX without subsequent warming hold period

    Device: localized heat therapy

Interventions

  • Devicelocalized heat therapy

    Blink-assisted, open eye therapy. Heat (45 degrees C) applied for 15 minutes to the upper and lower eyelids, followed by manual expression of the meibomian glands.

06

What researchers measure

Primary outcomes

  1. Mean Difference Between Eyes in Meibomian Gland Secretion Score (MGSS)

    The Meibomian Gland Secretion Score (MGSS) grades the consistency of secretions from the meibomian glands. Fifteen meibomian glands in each of the lower eyelids were gently pressed and the secretions were scored on the scale below. Sum of the grade (0 - 3) for each of the 15 glands. Range for this score is 0-45. A higher number indicates more normal meibomian gland activity. Score Description of Secretion: 0 - Nothing 1. \- Toothpaste 2. \- Cloudy 3. \- Clear The difference between eyes in the MGSS is the score for the right eye minus the score for the left eye. The mean is the arithmetic mean of this difference for all subjects.

    Time frame: MGSS used to calculate the difference in MGSS between eyes is obtained post-treatment at the procedure visit (Day 0).

Secondary outcomes

  1. Mean Change From Screening Visit Baseline in MGSS - Right Eye

    The Meibomian Gland Secretion Score (MGSS) grades the consistency of secretions from the meibomian glands. Fifteen meibomian glands in each of the lower eyelids were gently pressed and the secretions were scored on the scale below. Sum of the grade (0 - 3) for each of the 15 glands. Range for this score is 0-45. A higher number indicates more normal meibomian gland activity. Score Description of Secretion: 0 - Nothing 1 - Toothpaste 2 - Cloudy 3 - Clear The change from baseline in the MGSS is the score obtained following treatment at the procedure visit minus the score obtained for the same eye at the Screening visit. The mean is the arithmetic mean of this difference for all eyes. The right eye was the first eye expressed post-procedure.

    Time frame: MGSS is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)

  2. Mean Change From Screening Visit Baseline in MGSS - Left Eye

    The Meibomian Gland Secretion Score (MGSS) grades the consistency of secretions from the meibomian glands. Fifteen meibomian glands in each of the lower eyelids were gently pressed and the secretions were scored on the scale below. Sum of the grade (0 - 3) for each of the 15 glands. Range for this score is 0-45. A higher number indicates more normal meibomian gland activity. Score Description of Secretion: 0 - Nothing 1 - Toothpaste 2 - Cloudy 3 - Clear The change from baseline in the MGSS is the score obtained following treatment at the procedure visit minus the score obtained for the same eye at the Screening visit. The mean is the arithmetic mean of this difference for all eyes. The left eye was the second eye expressed post-procedure.

    Time frame: MGSS is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)

  3. Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Right Eye

    The Meibomian glands yielding any liquid (MGYAL) is the number of glands in the lower eyelid secreting any liquid, (regardless of graded quality). The score can range from 0 (no glands secreting liquid), to 15 (all 15 glands with liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYAL at screening and the MGYAL post-procedure at the procedure visit. The right eye was the first eye expressed post-procedure.

    Time frame: MGYAL is assessed at the Screening visit (Day -30 to -7) and at the Procedure visit (Day 0)

  4. Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Left Eye

    The Meibomian glands yielding any liquid (MGYAL) is the number of glands in the lower eyelid secreting any liquid, (regardless of graded quality). The score can range from 0 (no glands secreting liquid), to 15 (all 15 glands with liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYAL at screening and the MGYAL post-procedure at the procedure visit. The left eye was the second eye expressed post-procedure.

    Time frame: MGYAL is assessed at the Screening visit (Day -30 to -7) and at the Procedure visit (Day 0)

  5. Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Right Eye

    The Meibomian glands yielding clear liquid (MGYCL) is the number of glands in the lower eyelid secreting clear liquid. The score can range from 0 (no glands secreting clear liquid), to 15 (all 15 glands with clear liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYCL at screening and the MGYCL post-procedure at the procedure visit. The right eye was the first eye expressed post-procedure.

    Time frame: MGYCL is assessed at the Screening visit (Day -30 to Day -7) and post-treatment at the Procedure visit (Day 0)

  6. Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Left Eye

    The Meibomian glands yielding clear liquid (MGYCL) is the number of glands in the lower eyelid secreting clear liquid. The score can range from 0 (no glands secreting clear liquid), to 15 (all 15 glands with clear liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYCL at screening and the MGYCL post-procedure at the procedure visit. The left eye was the second eye expressed post-procedure.

    Time frame: MGYCL is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)

  7. Subject Comfort During Expression of Second Lid

    Subject Comfort during expression of second lid is assessed following treatment using a subject completed Likert scale rating the relative comfort of eyelid gland expression for the first lid expressed versus the second.

    Time frame: Subject Comfort during expression of second lid is assessed post-treatment at the Procedure visit (Day 0)

  8. Ease of Expression

    Ease of expression is assessed following treatment using a masked-assessor completed Likert scale rating the relative ease of eyelid gland expression for the first lid expressed versus the second.

    Time frame: Ease of expression is assessed following treatment at the Procedure visit (Day 0)

07

Results

Posted Nov 13, 2026

Participant flow

Subjects were recruited for the study between March 17, 2026 and April 16, 2026 at a comprehensive ophthalmic/optometric practice in Brecksville, OH.

Participant flow — Overall Study
MilestoneTearCare MGX With Warming HoldTearCare MGX Without Warming Hold
Started1110
Completed1110
Not completed00

Outcome measures

PrimaryMean Difference Between Eyes in Meibomian Gland Secretion Score (MGSS)

The Meibomian Gland Secretion Score (MGSS) grades the consistency of secretions from the meibomian glands. Fifteen meibomian glands in each of the lower eyelids were gently pressed and the secretions were scored on the scale below. Sum of the grade (0 - 3) for each of the 15 glands. Range for this score is 0-45. A higher number indicates more normal meibomian gland activity. Score Description of Secretion: 0 - Nothing 1. \- Toothpaste 2. \- Cloudy 3. \- Clear The difference between eyes in the MGSS is the score for the right eye minus the score for the left eye. The mean is the arithmetic mean of this difference for all subjects.

Time frame:
MGSS used to calculate the difference in MGSS between eyes is obtained post-treatment at the procedure visit (Day 0).
Reported as:
Mean · meibomian gland score
Mean Difference Between Eyes in Meibomian Gland Secretion Score (MGSS)
meibomian gland scoreTearCare MGX With Warming HoldTearCare MGX Without Warming Hold
Mean Difference Between Eyes in Meibomian Gland Secretion Score (MGSS)-0.4 ± 4.83.8 ± 4.6
Statistical analysis
  • TearCare MGX With Warming Hold vs TearCare MGX Without Warming Hold · t-test, 1 sided · p = <0.03
SecondaryMean Change From Screening Visit Baseline in MGSS - Right Eye

The Meibomian Gland Secretion Score (MGSS) grades the consistency of secretions from the meibomian glands. Fifteen meibomian glands in each of the lower eyelids were gently pressed and the secretions were scored on the scale below. Sum of the grade (0 - 3) for each of the 15 glands. Range for this score is 0-45. A higher number indicates more normal meibomian gland activity. Score Description of Secretion: 0 - Nothing 1 - Toothpaste 2 - Cloudy 3 - Clear The change from baseline in the MGSS is the score obtained following treatment at the procedure visit minus the score obtained for the same eye at the Screening visit. The mean is the arithmetic mean of this difference for all eyes. The right eye was the first eye expressed post-procedure.

Time frame:
MGSS is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)
Reported as:
Mean · meibomian gland score
Mean Change From Screening Visit Baseline in MGSS - Right Eye
meibomian gland scoreTearCare MGX With Warming HoldTearCare MGX Without Warming Hold
Mean Change From Screening Visit Baseline in MGSS - Right Eye15.8 ± 6.515.3 ± 5.2
Statistical analysis
  • TearCare MGX With Warming Hold vs TearCare MGX Without Warming Hold · t-test, 1 sided · p = <0.0001
SecondaryMean Change From Screening Visit Baseline in MGSS - Left Eye

The Meibomian Gland Secretion Score (MGSS) grades the consistency of secretions from the meibomian glands. Fifteen meibomian glands in each of the lower eyelids were gently pressed and the secretions were scored on the scale below. Sum of the grade (0 - 3) for each of the 15 glands. Range for this score is 0-45. A higher number indicates more normal meibomian gland activity. Score Description of Secretion: 0 - Nothing 1 - Toothpaste 2 - Cloudy 3 - Clear The change from baseline in the MGSS is the score obtained following treatment at the procedure visit minus the score obtained for the same eye at the Screening visit. The mean is the arithmetic mean of this difference for all eyes. The left eye was the second eye expressed post-procedure.

Time frame:
MGSS is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)
Reported as:
Mean · meibomian gland score
Mean Change From Screening Visit Baseline in MGSS - Left Eye
meibomian gland scoreTearCare MGX With Warming HoldTearCare MGX Without Warming Hold
Mean Change From Screening Visit Baseline in MGSS - Left Eye15.0 ± 3.910.9 ± 6.1
Statistical analysis
  • TearCare MGX With Warming Hold vs TearCare MGX Without Warming Hold · t-test, 1 sided · p = <0.0001
  • TearCare MGX With Warming Hold vs TearCare MGX Without Warming Hold · t-test, 1 sided · p = <0.05
SecondaryMean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Right Eye

The Meibomian glands yielding any liquid (MGYAL) is the number of glands in the lower eyelid secreting any liquid, (regardless of graded quality). The score can range from 0 (no glands secreting liquid), to 15 (all 15 glands with liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYAL at screening and the MGYAL post-procedure at the procedure visit. The right eye was the first eye expressed post-procedure.

Time frame:
MGYAL is assessed at the Screening visit (Day -30 to -7) and at the Procedure visit (Day 0)
Reported as:
Mean · number of glands with any liquid
Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Right Eye
number of glands with any liquidTearCare MGX With Warming HoldTearCare MGX Without Warming Hold
Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Right Eye7.8 ± 1.87.4 ± 2.5
Statistical analysis
  • TearCare MGX With Warming Hold vs TearCare MGX Without Warming Hold · t-test, 1 sided · p = <0.0001
SecondaryMean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Left Eye

The Meibomian glands yielding any liquid (MGYAL) is the number of glands in the lower eyelid secreting any liquid, (regardless of graded quality). The score can range from 0 (no glands secreting liquid), to 15 (all 15 glands with liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYAL at screening and the MGYAL post-procedure at the procedure visit. The left eye was the second eye expressed post-procedure.

Time frame:
MGYAL is assessed at the Screening visit (Day -30 to -7) and at the Procedure visit (Day 0)
Reported as:
Mean · number of glands with any liquid
Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Left Eye
number of glands with any liquidTearCare MGX With Warming HoldTearCare MGX Without Warming Hold
Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Left Eye7.6 ± 2.26.3 ± 2.8
Statistical analysis
  • TearCare MGX With Warming Hold vs TearCare MGX Without Warming Hold · t-test, 1 sided · p = <0.0001
  • TearCare MGX With Warming Hold vs TearCare MGX Without Warming Hold · t-test, 1 sided · p = =0.12
SecondaryMean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Right Eye

The Meibomian glands yielding clear liquid (MGYCL) is the number of glands in the lower eyelid secreting clear liquid. The score can range from 0 (no glands secreting clear liquid), to 15 (all 15 glands with clear liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYCL at screening and the MGYCL post-procedure at the procedure visit. The right eye was the first eye expressed post-procedure.

Time frame:
MGYCL is assessed at the Screening visit (Day -30 to Day -7) and post-treatment at the Procedure visit (Day 0)
Reported as:
Mean · number of glands with clear liquid
Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Right Eye
number of glands with clear liquidTearCare MGX With Warming HoldTearCare MGX Without Warming Hold
Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Right Eye1.5 ± 21.7 ± 1
SecondaryMean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Left Eye

The Meibomian glands yielding clear liquid (MGYCL) is the number of glands in the lower eyelid secreting clear liquid. The score can range from 0 (no glands secreting clear liquid), to 15 (all 15 glands with clear liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYCL at screening and the MGYCL post-procedure at the procedure visit. The left eye was the second eye expressed post-procedure.

Time frame:
MGYCL is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)
Reported as:
Mean · number of glands with clear liquid
Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Left Eye
number of glands with clear liquidTearCare MGX With Warming HoldTearCare MGX Without Warming Hold
Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Left Eye0.7 ± 10.5 ± 1
SecondarySubject Comfort During Expression of Second Lid

Subject Comfort during expression of second lid is assessed following treatment using a subject completed Likert scale rating the relative comfort of eyelid gland expression for the first lid expressed versus the second.

Time frame:
Subject Comfort during expression of second lid is assessed post-treatment at the Procedure visit (Day 0)
Reported as:
Count of participants · Participants
Subject Comfort During Expression of Second Lid
ParticipantsTearCare MGX With Warming HoldTearCare MGX Without Warming Hold
Comfort much better for 1st eye than 2nd eye32
Comfort somewhat better for 1st eye than 2nd eye02
Neutral65
Comfort somewhat better for 2nd eye than 1st eye00
Comfort much better for 2nd eye than 1st eye21
SecondaryEase of Expression

Ease of expression is assessed following treatment using a masked-assessor completed Likert scale rating the relative ease of eyelid gland expression for the first lid expressed versus the second.

Time frame:
Ease of expression is assessed following treatment at the Procedure visit (Day 0)
Reported as:
Count of participants · Participants
Ease of Expression
ParticipantsTearCare MGX With Warming HoldTearCare MGX Without Warming Hold
Much easier for the first eye than for the second eye00
Somewhat easier for the first eye than for the second eye13
Neutral86
Somewhat easier for the second eye than for the first eye21
Much easier for the second eye than for the first eye00

Adverse events

Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TearCare MGX With Warming Hold0/11 (0%)0/11 (0%)0/11 (0%)
TearCare MGX Without Warming Hold0/10 (0%)0/10 (0%)1/10 (10%)
Most frequent other events
Most frequent other events
EventTearCare MGX With Warming HoldTearCare MGX Without Warming Hold
erythemaSkin and subcutaneous tissue disorders0/111/10
eyelid irritationSkin and subcutaneous tissue disorders0/111/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TearCare MGX With Warming HoldTearCare MGX Without Warming HoldTotal
<=18 years000
Between 18 and 65 years459
>=65 years7512
Age, Continuous
Age, Continuous(years)TearCare MGX With Warming HoldTearCare MGX Without Warming HoldTotal
Mean63.8 ± 16.163.5 ± 13.263.7 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)TearCare MGX With Warming HoldTearCare MGX Without Warming HoldTotal
Female8816
Male325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TearCare MGX With Warming HoldTearCare MGX Without Warming HoldTotal
Hispanic or Latino000
Not Hispanic or Latino111021
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TearCare MGX With Warming HoldTearCare MGX Without Warming HoldTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White11920
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)TearCare MGX With Warming HoldTearCare MGX Without Warming HoldTotal
United States111021
Ocular Surface Disease Index (OSDI)
Ocular Surface Disease Index (OSDI)(units on a scale)TearCare MGX With Warming HoldTearCare MGX Without Warming HoldTotal
Mean35.4 ± 10.335.7 ± 15.935.6 ± 12.9
Meibomian Gland Secretion Score (MGSS) - right eye
Meibomian Gland Secretion Score (MGSS) - right eye(Meibomian Gland Secretion Score)TearCare MGX With Warming HoldTearCare MGX Without Warming HoldTotal
Mean7.5 ± 2.07.6 ± 2.67.5 ± 2.2

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Cleveland Eye Clinic
    Brecksville, Ohio 44141, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Protection of patient confidentiality.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in May 2026, 2 months.

Results were first posted in Nov 2026, 5 months after primary completion.

Of 23 industry-sponsored interventional studies with no phase under Meibomian Gland Dysfunction, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 2 months is below that.

Counting every sponsor, half of 75 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 26, 2026
StartActual
Mar 17, 2026
Primary completionActual
May 19, 2026
CompletionActual
May 19, 2026
Results first posted
Nov 13, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedMean difference between eyesDifference Between Eyes in Meibomian Gland Secretion Score (MGSS)Time frame: MGSS used to calculate the difference in MGSS between eyes is obtained post-treatment at the procedure visit (Day 0).
Nov 13, 2026
Documents
Secondary outcomes
5 edited, 3 added
What changed in the outcomes
  • EditedMean change fromChange From Screening visit baselineVisit Baseline in MGSS - Right EyeTime frame: MGSS is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)
  • EditedMean change fromChange From Screening visit baselineVisit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL)MGSS - Left EyeTime frame: MGYAL is assessed at the Screening visit (Day -30 to -7) and at the Procedure visit (Day 0) → MGSS is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)
  • EditedMean change fromChange From Screening visit baselineVisit Baseline in Meibomian Glands Yielding ClearAny Liquid (MGYCLMGYAL) - Right EyeTime frame: MGYCL is assessed at the Screening visit (Day -30 to Day -7) and post-treatment at the Procedure visit (Day 0) → MGYAL is assessed at the Screening visit (Day -30 to -7) and at the Procedure visit (Day 0)
  • EditedSubject Comfort during expressionDuring Expression of second lidSecond LidTime frame: Subject Comfort during expression of second lid is assessed post-treatment at the Procedure visit (Day 0)
  • EditedEase of expressionExpressionTime frame: Ease of expression is assessed following treatment at the Procedure visit (Day 0)
  • AddedMean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Left EyeTime frame: MGYAL is assessed at the Screening visit (Day -30 to -7) and at the Procedure visit (Day 0)
  • AddedMean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Right EyeTime frame: MGYCL is assessed at the Screening visit (Day -30 to Day -7) and post-treatment at the Procedure visit (Day 0)
  • AddedMean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Left EyeTime frame: MGYCL is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedMean difference between eyesDifference Between Eyes in Meibomian Gland Secretion Score (MGSS)Time frame: MGSS used to calculate the difference in MGSS between eyes is obtained post-treatment at the procedure visit (Day 0).
    Secondary outcomes 5 edited, 3 added
    What changed in the outcomes
    • EditedMean change fromChange From Screening visit baselineVisit Baseline in MGSS - Right EyeTime frame: MGSS is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)
    • EditedMean change fromChange From Screening visit baselineVisit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL)MGSS - Left EyeTime frame: MGYAL is assessed at the Screening visit (Day -30 to -7) and at the Procedure visit (Day 0) → MGSS is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)
    • EditedMean change fromChange From Screening visit baselineVisit Baseline in Meibomian Glands Yielding ClearAny Liquid (MGYCLMGYAL) - Right EyeTime frame: MGYCL is assessed at the Screening visit (Day -30 to Day -7) and post-treatment at the Procedure visit (Day 0) → MGYAL is assessed at the Screening visit (Day -30 to -7) and at the Procedure visit (Day 0)
    • EditedSubject Comfort during expressionDuring Expression of second lidSecond LidTime frame: Subject Comfort during expression of second lid is assessed post-treatment at the Procedure visit (Day 0)
    • EditedEase of expressionExpressionTime frame: Ease of expression is assessed following treatment at the Procedure visit (Day 0)
    • AddedMean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Left EyeTime frame: MGYAL is assessed at the Screening visit (Day -30 to -7) and at the Procedure visit (Day 0)
    • AddedMean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Right EyeTime frame: MGYCL is assessed at the Screening visit (Day -30 to Day -7) and post-treatment at the Procedure visit (Day 0)
    • AddedMean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Left EyeTime frame: MGYCL is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07365735
Lead sponsor
Sight Sciences, Inc.
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
Mar 17, 2026
Primary completion
May 19, 2026
Completion
May 19, 2026
Results posted
Nov 13, 2026
Last update
Nov 13, 2026

Study contacts

Thomas Chester, OD
principal investigator · Cleveland Eye Clinic
Jaime Dickerson, PhD
study director · Sight Sciences, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion